Progress toward development of vaccines against melioidosis: A review

Clinical Therapeutics

Volumn 32, Issue 8, 2010, Pages 1437-1445

  Sarkar Tyson, Mitali ^a   Titball, Richard W ^b  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Inactivated vaccines; Live vaccines; Melioidosis; Subunit vaccines; Vaccines

Indexed keywords

BACTERIAL ANTIGEN; BURKHOLDERIA PSEUDOMALLEI VACCINE; DNA VACCINE; INACTIVATED VACCINE; LIVE VACCINE; POLYSACCHARIDE VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

AIRBORNE INFECTION; BACTERIAL STRAIN; BURKHOLDERIA PSEUDOMALLEI; HUMAN; IMMUNE RESPONSE; IMMUNITY; MEDLINE; MELIOIDOSIS; NONHUMAN; REVIEW;

ANIMALS; BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HUMANS; MELIOIDOSIS; MICE;

EID: 77955880301     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.020     Document Type: Review

References (68)

1. Cheng AC, Currie BJ Melioidosis: Epidemiology, pathophysiology, and management [published correction appears in Clin Microbiol Rev. 2007;20:533]. Clin Microbiol Rev. 2005, 18:383-416.
2. Dance DA Melioidosis: The tip of the iceberg?. Clin Microbiol Rev. 1991, 4:52-60.
3. Wuthiekanun V, Peacock SJ Management of melioidosis. Expert Rev Anti Infect Ther. 2006, 4:445-455.
4. Wiersinga WJ, van der Poll T, White NJ, et al. Melioidosis: Insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol. 2006, 4:272-282.
5. Suputtamongkol Y, Chaowagul W, Chetchotisadk P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis. 1999, 29:408-413.
6. White NJ Melioidosis. Lancet 2003, 361:1715-1722.
7. Currie BJ, Dance DA, Cheng AC The global distribution of Burkholderia pseudomallei and melioidosis: An update. Trans R Soc Trop Med Hyg. 2008, 102(Suppl 1):S1-S4.
8. Currie BJ Melioidosis: An important cause of pneumonia in residents of and travellers returned from endemic regions. Eur Respir J. 2003, 22:542-550.
9. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol. 2005, 43:970-972.
10. Titball RW, Russell P, Cuccui J, et al. Burkholderia pseudo-mallei: Animal models of infection. Trans R Soc Trop Med Hyg. 2008, 102(Suppl 1):S111-S116.
11. Mills CD, Kincaid K, Alt JM, et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000, 164:6166-6173.
12. Leakey AK, Ulett GC, Hirst RG BALB/c and C57BI/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb Pathog. 1998, 24:269-275.
13. Tan GY, Liu Y, Sivalingam SP, et al. Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57BI/6 mice. J Med Microbiol. 2008, 57:508-515.
14. Ulett GC, Ketheesan N, Hirst RG Cytokine gene expression in innately susceptable BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect Immun. 2000, 68:2034-2042.
15. Ulett GC, Ketheesan N, Hirst RG Proinflammatory cytokine mRNA responses in experimental Burkholderia pseudomallei infection in mice. Acta Trop. 2000, 74:229-234.
16. Wiersinga WJ, Dessing MC, van der Poll T Gene-expression profiles in murine melioidosis. Microbes Infect. 2008, 10:868-877.
17. Wiersinga WJ, de Vos AF, de Beer R, et al. Inflammation patterns induced by different Burkholderia species in mice. Cell Microbiol. 2008, 10:81-87.
18. Brown AE, Dance DA, Suputtamongkol Y, et al. Immune cell activation in melioidosis: Increased serum levels of interferon-gamma and soluble interleukin-2 receptors without change in soluble CD8 protein. J Infect Dis. 1991, 163:1145-1148.
19. Suputtamongkol Y, Kwiatkowski D, Dance DA, et al. Tumor necrosis factor in septicemic melioidosis. J Infect Dis. 1992, 165:561-564.
20. Ulett GC, Labrooy JT, Currie BJ, et al. A model of immunity to Burkholderia pseudomallei: Unique responses following immunization and acute lethal infection. Microbes Infect. 2005, 7:1263-1275.
21. LeVine AM, Reed JA, Kurak KE, et al. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest. 1999, 103:563-569.
22. Nelson M, Prior JL, Lever MS, et al. Evaluation of lipopoly-saccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol. 2004, 53:1177-1182.
23. Brett PJ, Woods DE Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun. 1996, 64:2824-2828.
24. Jones SM, Ellis JF, Russell P, et al. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol. 2002, 51:1055-1062.
25. Bottex C, Gauthier YP, Hagen RM, et al. Attempted passive prophylaxis with a monoclonal antti-Burkholderia pseudomallei exopolysaccharide antibody in a murine model of melioidosis. Immunopharmacol Immunotoxicol 2005, 27:565-583.
26. Ho M, Schollaardt T, Smith MD, et al. Specificity and functional activity of anti-Burkholderia pseudomallei poly-saccharide antibodies. Infect Immun. 1997, 65:3648-3653.
27. Harding SV, Sarkar-Tyson M, Smither SJ, et al. The identification of surface proteins of Burkholderia pseudomallei. Vaccine 2007, 25:2664-2672.
28. Felgner PL, Kayala MA, Vigil A, et al. A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A 2009, 106:13499-13504.
29. Sarkar-Tyson M, Smither SJ, Harding SV, et al. Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine 2009, 27:4447-4451.
30. Lauw FN, Simpson AJ, Hack CE, et al. Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria. J Infect Dis. 2000, 182:206-213.
31. Barnes JL, Warner J, Melrose W, et al. Adaptive immunity in melioidosis: A possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin Immunol. 2004, 113:22-28.
32. Haque A, Easton A, Smith D, et al. Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J Infect Dis. 2006, 193:370-379.
33. Santanirand P, Harley VS, Dance DA, et al. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 1999, 67:3593-3600.
34. Haque A, Chu K, Easton A, et al. A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J Infect Dis. 2006, 194:1241-1248.
35. Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol. 2001, 166:1097-1105.
36. Tippayawat P, Saenwongsa W, Mahawantung J, et al. Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl Trop Dis. 2009, 3:e407.
37. Arya SC, Agarwal N Re: Typhoid fever vaccines: Systematic review and meta-analysis of randomised clinical trials [comment]. Vaccine 2008, 26:291.
38. Hawkridge A Clinical studies of TB vaccines. Hum Vaccin 2009, 5:773-776.
39. Atkins T, Prior P, Mack K, et al. Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol. 2002, 51:539-547.
40. Rodrigues F, Sarkar-Tyson M, Harding SV, et al. Global map of growthregulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. J Bacteriol. 2006, 188:8178-8188.
41. Cuccui J, Easton A, Chu KK, et al. Development of signature-tagged mutagenesis in Burkholderia pseudo-mallei to identify genes important in survival and pathogenesis. Infect Immun. 2007, 75:1186-1195.
42. Breitbach K, Köhler J, Steinmetz I Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans R Soc Trop Med Hyg. 2008, 102(Suppl 1):S89-S94.
43. Stevens MP, Haque A, Atkins T, et al. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 2004, 150:2669-2676.
44. Srilunchang T, Proungvitaya T, Wongratanacheewin S, et al. Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2. Southeast Asian J Trop Med Public Health 2009, 40:123-130.
45. Plotkin SA Vaccines: The fourth century. Clin Vaccine Immunol. 2009, 16:1709-1719.
46. Barnes JL, Ketheesan N Development of protective immunity in a murine model of melioidosis is influenced by the source of Burkholderia pseudomallei antigens. Immunol Cell Biol. 2007, 85:551-557.
47. Razak CE, Ismail G, Embim N, Omar O Protection studies using whole cells and partially purified toxic material (PPTM) of Pseudomonas pseudomallei. Malays Appl Biol. 1986, 15:105-111.
48. Klinman DM Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol. 2006, 25:135-154.
49. Elvin SJ, Healey GD, Westwood A, et al. Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun. 2006, 74:1706-1711.
50. Bambini S, Rappuoli R The use of genomics in microbial vaccine development. Drug Discov Today 2009, 14:252-260.
51. Reckseidler S, DeShazer D, Sokol PA, Woods DE Detection of bacterial virulence genes by subtractive hybridization: Identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun. 2001, 69:34-44.
52. DeShazer D, Brett PJ, Woods DE The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol. 1998, 30:1081-1100.
53. Sarkar-Tyson M, Thwaite JE, Harding SV, et al. Polysaccharides and virulence of Burkholderia pseudomallei. J Med Microbiol. 2007, 56:1005-1010.
54. Bryan LE, Wong S, Woods DE, et al. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can J Infect Dis. 1994, 5:170-178.
55. Holden MT, Titball RW, Peacock SJ, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 2004, 101:14240-14245.
56. Reckseidler-Zenteno SL, Moore R, Woods DE Genetics and function of the capsules of Burkholderia pseudomallei and their potential as therapeutic targets. Mini Rev Med Chem. 2009, 9:265-271.
57. Nimtz M, Wray V, Domke T, et al. Structure of an acidic exopolysaccharide of Burkholderia pseudomallei. Eur J Biochem. 1997, 250:608-616.
58. Steinmetz I, Rohde M, Brenneke B Purification and characterization of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. Infect Immun. 1995, 63:3959-3965.
59. Steinmetz I, Nimtz M, Wray V, et al. Exopolysaccharides of Burkholderia pseudomallei. Acta Trop. 2000, 74:211-214.
60. Jitsurong S, Chirathaworn C, Brown NF, et al. Searching for virulence Burkholderia pseudomallei genes by immunoscreening a lambda ZAPII expressed genomic library. Southeast Asian J Trop Med Public Health 2003, 34:810-821.
61. Harland DN, Chu K, Haque A, et al. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun. 2007, 75:4173-4180.
62. Hara Y, Mohamed R, Nathan S Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets. PLoS One. 2009, 4:e6496.
63. Chen YS, Hsiao YS, Lin HH, et al. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine 2006, 24:750-758.
64. Chen YS, Hsiao YS, Lin HH, et al. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine 2006, 24:750-758.
65. Jones C Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc. 2005, 77:293-324.
66. Wuorimaa T, Käyhty H, Eskola J, et al. Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand J Immunol. 2001, 53:422-428.
67. Charoenwong P, Lumbiganon P, Puapermpoonsiri S The prevalence of the indirect hemagglutination test for melioidosis in children in an endemic area. Southeast Asian J Trop Med Public Health 1992, 23:698-701.
68. Mackowiak PA, Smith JW Septicemic melioidosis. Occurrence following acute influenza A six years after exposure in Vietnam. JAMA 1978, 240:764-766.